These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 24294372)
1. KAT5 and KAT6B are in positive regulation on cell proliferation of prostate cancer through PI3K-AKT signaling. He W; Zhang MG; Wang XJ; Zhong S; Shao Y; Zhu Y; Shen ZJ Int J Clin Exp Pathol; 2013; 6(12):2864-71. PubMed ID: 24294372 [TBL] [Abstract][Full Text] [Related]
2. SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway. Quan Y; Wang N; Chen Q; Xu J; Cheng W; Di M; Xia W; Gao WQ Oncotarget; 2015 Sep; 6(28):26494-507. PubMed ID: 26317998 [TBL] [Abstract][Full Text] [Related]
3. Vacuolar protein sorting-associated protein 72 homolog (VPS72) binding to lysine acetyltransferase 5 (KAT5) promotes the proliferation, invasion and migration of hepatocellular carcinoma through regulating phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. Chen T; Tu Y; Lv D; Lin K; Tang H; Huang W Bioengineered; 2022 Apr; 13(4):9197-9210. PubMed ID: 35383533 [TBL] [Abstract][Full Text] [Related]
4. KAT5 silencing induces apoptosis of GBC-SD cells through p38MAPK-mediated upregulation of cleaved Casp9. Feng FL; Yu Y; Liu C; Zhang BH; Cheng QB; Li B; Tan WF; Luo XJ; Jiang XQ Int J Clin Exp Pathol; 2014; 7(1):80-91. PubMed ID: 24427328 [TBL] [Abstract][Full Text] [Related]
5. Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis. Duan S; Moro L; Qu R; Simoneschi D; Cho H; Jiang S; Zhao H; Chang Q; de Stanchina E; Arbini AA; Pagano M Cell Rep; 2021 Oct; 37(3):109870. PubMed ID: 34686346 [TBL] [Abstract][Full Text] [Related]
6. Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer. Han G; Zhang X; Liu P; Yu Q; Li Z; Yu Q; Wei X Int J Oncol; 2018 Nov; 53(5):2056-2066. PubMed ID: 30132513 [TBL] [Abstract][Full Text] [Related]
7. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression. Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280 [TBL] [Abstract][Full Text] [Related]
8. THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway. Hou Y; Li H; Huo W Prostate; 2020 Jul; 80(10):753-763. PubMed ID: 32421868 [TBL] [Abstract][Full Text] [Related]
9. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway. Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507 [TBL] [Abstract][Full Text] [Related]
10. Histone acetylation and histone acetyltransferases show significant alterations in human abdominal aortic aneurysm. Han Y; Tanios F; Reeps C; Zhang J; Schwamborn K; Eckstein HH; Zernecke A; Pelisek J Clin Epigenetics; 2016; 8():3. PubMed ID: 26767057 [TBL] [Abstract][Full Text] [Related]
11. Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding. Lv D; Jia F; Hou Y; Sang Y; Alvarez AA; Zhang W; Gao WQ; Hu B; Cheng SY; Ge J; Li Y; Feng H Cancer Res; 2017 Nov; 77(22):6190-6201. PubMed ID: 29021135 [TBL] [Abstract][Full Text] [Related]
12. The PI3K/AKT pathway in the pathogenesis of prostate cancer. Chen H; Zhou L; Wu X; Li R; Wen J; Sha J; Wen X Front Biosci (Landmark Ed); 2016 Jun; 21(5):1084-91. PubMed ID: 27100493 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer. Ma T; Chen H; Wang P; Yang N; Bao J Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162 [No Abstract] [Full Text] [Related]
14. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer. Liu Z; Zhu G; Getzenberg RH; Veltri RW J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606 [TBL] [Abstract][Full Text] [Related]
15. PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P. Huang B; Fu SJ; Fan WZ; Wang ZH; Chen ZB; Guo SJ; Chen JX; Qiu SP Cancer Lett; 2016 Jun; 376(1):148-54. PubMed ID: 27037060 [TBL] [Abstract][Full Text] [Related]
16. Isoforms S and L of MRPL33 from alternative splicing have isoform‑specific roles in the chemoresponse to epirubicin in gastric cancer cells via the PI3K/AKT signaling pathway. Li J; Feng D; Gao C; Zhang Y; Xu J; Wu M; Zhan X Int J Oncol; 2019 May; 54(5):1591-1600. PubMed ID: 30816492 [TBL] [Abstract][Full Text] [Related]
17. FGF21 facilitates autophagy in prostate cancer cells by inhibiting the PI3K-Akt-mTOR signaling pathway. Dai H; Hu W; Zhang L; Jiang F; Mao X; Yang G; Li L Cell Death Dis; 2021 Mar; 12(4):303. PubMed ID: 33753729 [TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase. Gesmundo I; Di Blasio L; Banfi D; Villanova T; Fanciulli A; Favaro E; Gamba G; Musuraca C; Rapa I; Volante M; Munegato S; Papotti M; Gontero P; Primo L; Ghigo E; Granata R Cancer Lett; 2019 May; 449():252-262. PubMed ID: 30790678 [TBL] [Abstract][Full Text] [Related]
19. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Patani N; Jiang WG; Newbold RF; Mokbel K Anticancer Res; 2011 Dec; 31(12):4115-25. PubMed ID: 22199269 [TBL] [Abstract][Full Text] [Related]
20. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]